Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.34 |
| ▸ | FABP7 | O15540 | 2/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.34 |
| ▸ | CASP3 | P42574 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23042936 | 1.00 | MDM4 (0.37) | MDM4TP53KMT2AMDM2FABP7 | |
| SCHEMBL29879964 | 1.00 | MDM4 (0.37) | MDM4TP53KMT2AMDM2FABP7 | |
| SCHEMBL30861275 | 0.86 | MDM2 (0.38) | MDM4TP53KMT2AMDM2CASP3 | |
| SCHEMBL8892691 | 0.86 | KMT2A (0.38) | MDM4TP53KMT2AMDM2FABP7 | |
| SCHEMBL16166754 | 0.85 | KMT2A (0.37) | MDM4TP53KMT2AMDM2FABP7 | |
| SCHEMBL28737117 | 0.85 | KMT2A (0.37) | MDM4TP53KMT2AMDM2FABP7 | |
| SCHEMBL1740786 | 0.84 | MDM4 (0.40) | MDM4TP53KMT2AMDM2FABP7 | |
| SCHEMBL2133987 | 0.82 | MDM2 (0.38) | MDM4TP53KMT2AMDM2FABP7 | |
| SCHEMBL22610140 | 0.82 | MDM2 (0.38) | MDM4TP53KMT2AMDM2FABP7 | |
| SCHEMBL23042935 | 0.81 | HIF1A (0.42) | MDM4TP53FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12577259-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4660303-A2 | PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-3810626-B1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250206781-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | US | disclosed |
| US-12209145-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2025-01-28 | — | — | US | disclosed |
| US-12178842-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| WO-2024259310-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-3810176-B1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | RA PHARMACEUTICALS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-3810177-B1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | RA PHARMACEUTICALS INC (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-3810626-A1 | PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3810177-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | RA Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3810129-A1 | PCSK9 ANTAGONIST BICYCLO-COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3810178-A2 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | MERCK SHARP & DOHME CORP. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-03-11 | — | — | US | disclosed |
| WO-2021041770-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2013135894-A1 | VERSATILE FUNCTIONALIZATION OF CARBON NANOSTRUCTURES | UNIVERSITE DE STRASBOURG (FR) | 2013-09-19 | — | — | WO | disclosed |
| EP-1226146-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | ABBOTT LABORATORIES | 2002-04-25 | — | — | US | disclosed |
| WO-2001032655-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MDM4 4763/4885TP53 4077/4885KMT2A 1433/4885 |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | NQO2, NQO1, NDUFA7 | MDM4 1706/4885TP53 986/4885KMT2A 3343/4885 |
| US-12178842-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | MDM4 4763/4885TP53 4077/4885KMT2A 1433/4885 |
| US-12577259-B2 | PCSK9 antagonist compounds | PCSK9, LDLR, PCSK6 | MDM4 4790/4885TP53 4774/4885KMT2A 2065/4885 |
| US-12209145-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | MDM4 4743/4885TP53 4401/4885KMT2A 1913/4885 |
| US-20250206781-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MDM4 4743/4885TP53 4401/4885KMT2A 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.